Novo Invests in Upgrading Kalundborg Manufacturing Facility

Novo Nordisk announced an investment of DKK 850M (~$135M USD) into expanding its production site in Kalundborg, Denmark. According to the press release, Novo manufactures half of the world’s insulin supply and carries out the assembly and packaging of diabetes and biopharm products at this site. This most recent investment brings Novo’s 2020 Kalundborg investments to nearly $318M USD. Below FENIX provides thoughts on the manufacturing investment in the context of the potential products it could support.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.